Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Naphthalene derivatives and their application in medicine

A drug and pharmaceutical technology, applied to the naphthalene compound of melatonin receptor agonist, the application field in the treatment of central nervous system dysfunction, can solve problems such as shortening sleep latency, and achieve good clinical application prospects and good efficacy. Effect

Inactive Publication Date: 2016-06-01
SUNSHINE LAKE PHARM CO LTD
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The melatonin receptor agonist ramelteon (ramelteon), which was first listed in the United States in 2005, is used for the treatment of insomnia, which can shorten the sleep latency, improve sleep efficiency and sleep maintenance. Compared with traditional drugs, this drug does not damage the Cognitive activities on the next day, no withdrawal symptoms; but this drug has mild side effects, such as headache, fatigue, lethargy, etc. (ArendtJ, VanSomerenEJ, AppletonR, eta1., Clinical update: melatoninandsleepdisorders. 383)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Naphthalene derivatives and their application in medicine
  • Naphthalene derivatives and their application in medicine
  • Naphthalene derivatives and their application in medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0227] Embodiment 1N-(2-(7-methoxynaphthalene-1-yl)-2-methylpropyl)acetamide

[0228]

[0229] Step 1) Synthesis of 2-(7-methoxy-3,4-dihydronaphthalen-1-yl)acetonitrile

[0230] 7-methoxy-3,4-dihydronaphthalene-1 (2H)-one (5.00g, 28.37mmol), 2-cyanoacetic acid (3.62g, 42.56mmol), heptanoic acid (1.0mg, 7.09 mmol) and benzylamine (0.78mL, 7.09mmol) were reacted in toluene (30mL) in an oil bath at 140°C for 48h, then the reaction was stopped and cooled to 25°C. It was washed successively with saturated sodium bicarbonate solution (100 mL) and saturated brine (40 mL), and the organic phase was dried over anhydrous sodium sulfate after separation. After filtration, the filtrate was spin-dried under reduced pressure, and purified by column chromatography (petroleum ether / ethyl acetate (v / v)=50 / 1) to obtain the title compound as a yellow solid (5.44 g, 96.3%).

[0231] MS(ESI,pos.ion)m / z:200.2[M+1] + ;

[0232] 1 HNMR (600MHz, CDCl 3 )δ7.12(d, J=8.4Hz, 1H), 6.77(dd, J=8...

Embodiment 2

[0250] Embodiment 2N-(2-(7-fluoronaphthalen-1-yl)-2-methylpropyl)acetamide

[0251]

[0252] Step 1) Synthesis of 2-(7-fluoro-3,4-dihydronaphthalen-1-yl)acetonitrile

[0253] The title compound of this step was prepared by referring to the method described in step 1 of Example 1, that is, 7-fluoro-3,4-dihydronaphthalene-1(2H)-one (2.00g, 12.18mmol), 2-cyanoacetic acid ( 1.55g, 18.27mmol), heptanoic acid (0.43mL, 3.05mmol) and benzylamine (0.33mL, 3.05mmol) were prepared by reacting in toluene (30mL), and the crude product was subjected to silica gel column chromatography (petroleum ether / ethyl acetate (v / v)=50 / 1), concentrated and dried to obtain the title compound as a yellow solid (1.03 g, 45.2%).

[0254] MS(ESI,pos.ion)m / z:188.2[M+1] + ;

[0255] 1HNMR (400MHz, CDCl 3 )δ7.13(dd, J=8.4,6.0Hz,1H),6.89(td,J=8.4,2.8Hz,1H),6.81(dd,J=9.6,2.8Hz,1H),6.33(t,J =4.4Hz, 1H), 3.45(dd, J=3.6, 1.6Hz, 2H), 2.76(t, J=8.0Hz, 2H), 2.36(m, 2H).

[0256] Step 2) Synthesis of 2-(...

Embodiment 3

[0270] Embodiment 3N-(2-(7-methoxynaphthalene-1-yl)-2-methylpropyl)propionamide

[0271]

[0272] Step 1) Synthesis of N-(2-(7-methoxynaphthalene-1-yl)-2-methylpropyl) propanamide

[0273] The title compound of this step was prepared by referring to the method described in step 5 of Example 1, that is, 2-(7-methoxynaphth-1-yl)-2-methylpropan-1-amine (195 mg, 850 μmol), triethylamine (240μL, 1.70mmol) and propionyl chloride (90μL, 1.28mmol) were prepared by reacting in dichloromethane (15mL), and the crude product was subjected to silica gel column chromatography (petroleum ether / ethyl acetate (v / v)=2 / 1) , concentrated to dryness to obtain the title compound as a white solid (189 mg, 78.1%).

[0274] MS(ESI,pos.ion)m / z:286.3[M+1] + ;

[0275] 1 HNMR (600MHz, CDCl 3 )δ7.81(d, J=1.8Hz, 1H), 7.77(d, J=9.0Hz, 1H), 7.69(d, J=8.4Hz, 1H), 7.41(d, J=7.8Hz, 1H) ,7.30(t,J=7.8Hz,1H),7.15(dd,J=9.0,2.4Hz,1H),3.98(s,3H),3.79(d,J=5.4Hz,2H),2.27(q, J=6.0Hz, 2H), 1.55(s, 6H), 1.02...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a number of naphthalene derivatives or stereoisomers, tautomers, nitrogen oxides, metabolites, pharmaceutically acceptable salts or prodrugs thereof which are used for excitement of melatonin receptors. The invention also discloses pharmaceutical compositions containing such compounds and application thereof in treatment of central nervous system dysfunction of mammals, especially human.

Description

technical field [0001] The invention belongs to the field of medicines, and in particular relates to a class of novel compounds that can be used for treating central nervous system dysfunction, their preparation methods, pharmaceutical compositions containing the compounds, and the role of the compounds and their pharmaceutical compositions in treating central nervous system dysfunction. applications in obstacles. More specifically, the present invention describes naphthalene compounds that can be used as melatonin receptor agonists. Background technique [0002] Melatonin is a neuroendocrine hormone secreted by the pineal gland. Its main physiological functions are: 1. Anti-tumor effect. Melatonin can inhibit breast cancer, melanoma, prostate cancer, liver cancer, etc. The growth of cancer cells is an important physiological tumor suppressor; 2. Antioxidation, the body can produce free radicals through enzymatic and non-enzymatic reactions, such as oxygen free radicals, hy...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07C233/18C07C233/13C07C231/02A61K31/165A61P25/00A61P25/20A61P25/24A61P25/22A61P25/18A61P25/08A61P25/16A61P25/28A61P25/06
Inventor 金传飞张英俊聂飚徐景宏蔡少瑜
Owner SUNSHINE LAKE PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com